2013
Impact of neoadjuvant chemotherapy plus HER2-targeting on breast conservation rates: Surgical results from CALGB 40601 (Alliance).
Ollila D, Berry D, Cirrincione C, Carey L, Amos K, Henry N, Winer E, Hudis C, Golshan M. Impact of neoadjuvant chemotherapy plus HER2-targeting on breast conservation rates: Surgical results from CALGB 40601 (Alliance). Journal Of Clinical Oncology 2013, 31: 501-501. DOI: 10.1200/jco.2013.31.15_suppl.501.Peer-Reviewed Original ResearchNeoadjuvant therapyBCT candidatesCALGB 40601Neoadjuvant chemotherapySystemic therapySurgical resultsBreast surgeonsBreast cancerTumor-free surgical marginsBreast cancer ptsNeoadjuvant systemic therapyOperable breast cancerBreast conservation ratesPhase III trialsAnti-HER2 treatmentModern systemic therapyBreast cancer operationsBCT eligibilityCancer ptsEligible patientsNeoadjuvant trialsTherapy ratesIII trialsSurgical marginsCancer operations
2008
Trends in Racial and Age Disparities in Definitive Local Therapy of Early-Stage Breast Cancer
Freedman RA, He Y, Winer EP, Keating NL. Trends in Racial and Age Disparities in Definitive Local Therapy of Early-Stage Breast Cancer. Journal Of Clinical Oncology 2008, 27: 713-719. PMID: 19103731, DOI: 10.1200/jco.2008.17.9234.Peer-Reviewed Original ResearchConceptsDefinitive local therapyBreast-conserving surgeryEarly-stage breast cancerLocal therapyBreast cancerHispanic womenStage I/II breast cancerEnd Results registry dataAsian womenReceipt of radiationMultivariate logistic regressionBreast cancer therapyRace/ethnicityMastectomy ratesTherapy ratesBreast conservationAdjusted analysisRegistry dataWomen 61Stage ITherapyAdult womenLogistic regressionCancerStudy period